SE9603408D0 - Medical use - Google Patents

Medical use

Info

Publication number
SE9603408D0
SE9603408D0 SE9603408A SE9603408A SE9603408D0 SE 9603408 D0 SE9603408 D0 SE 9603408D0 SE 9603408 A SE9603408 A SE 9603408A SE 9603408 A SE9603408 A SE 9603408A SE 9603408 D0 SE9603408 D0 SE 9603408D0
Authority
SE
Sweden
Prior art keywords
medical use
gastro
inhibition
treatment
receptor agonists
Prior art date
Application number
SE9603408A
Other languages
English (en)
Inventor
Anders Lehmann
Paul Andrews
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20403936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9603408(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9603408A priority Critical patent/SE9603408D0/sv
Publication of SE9603408D0 publication Critical patent/SE9603408D0/sv
Priority to ARP970104051A priority patent/AR007747A1/es
Priority to ZA9707969A priority patent/ZA977969B/xx
Priority to TW086113275A priority patent/TW548104B/zh
Priority to IDP973172A priority patent/ID19621A/id
Priority to EEP199900095A priority patent/EE03952B1/xx
Priority to UA99031298A priority patent/UA61081C2/uk
Priority to RU99107969/14A priority patent/RU2199316C2/ru
Priority to HU9903825A priority patent/HU224968B1/hu
Priority to DE69724809T priority patent/DE69724809T2/de
Priority to NZ334495A priority patent/NZ334495A/xx
Priority to SI9730594T priority patent/SI0936906T1/xx
Priority to KR1019997002239A priority patent/KR100553294B1/ko
Priority to KR1020057018539A priority patent/KR100568659B1/ko
Priority to DK97942346T priority patent/DK0936906T3/da
Priority to CN97199600A priority patent/CN1117560C/zh
Priority to IL12896197A priority patent/IL128961A/en
Priority to EP03013667A priority patent/EP1344524B1/en
Priority to NZ504244A priority patent/NZ504244A/xx
Priority to AT97942346T priority patent/ATE249212T1/de
Priority to CA002265615A priority patent/CA2265615C/en
Priority to US08/952,400 priority patent/US6117908A/en
Priority to TR1999/00591T priority patent/TR199900591T2/xx
Priority to PT03013667T priority patent/PT1344524E/pt
Priority to SK305-99A priority patent/SK285744B6/sk
Priority to PCT/SE1997/001555 priority patent/WO1998011885A1/en
Priority to CZ0093099A priority patent/CZ299997B6/cs
Priority to AU44064/97A priority patent/AU714370B2/en
Priority to EP97942346A priority patent/EP0936906B1/en
Priority to BR9711400A priority patent/BR9711400A/pt
Priority to DE69736445T priority patent/DE69736445T2/de
Priority to ES97942346T priority patent/ES2206749T3/es
Priority to AT03013667T priority patent/ATE334700T1/de
Priority to ES03013667T priority patent/ES2268227T3/es
Priority to PT97942346T priority patent/PT936906E/pt
Priority to PL97332497A priority patent/PL190028B1/pl
Priority to DK03013667T priority patent/DK1344524T3/da
Priority to SI9730749T priority patent/SI1344524T1/sl
Priority to JP51458198A priority patent/JP4098832B2/ja
Priority to MYPI97004296A priority patent/MY122020A/en
Priority to SA97180522A priority patent/SA97180522B1/ar
Priority to IS5001A priority patent/IS2329B/is
Priority to NO19991287A priority patent/NO326837B1/no
Priority to HK00101114A priority patent/HK1022100A1/xx
Priority to US09/658,242 priority patent/US6664069B1/en
Priority to HK03109347A priority patent/HK1057004A1/xx
Priority to IS8623A priority patent/IS2538B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE9603408A 1996-09-18 1996-09-18 Medical use SE9603408D0 (sv)

Priority Applications (47)

Application Number Priority Date Filing Date Title
SE9603408A SE9603408D0 (sv) 1996-09-18 1996-09-18 Medical use
ARP970104051A AR007747A1 (es) 1996-09-18 1997-09-04 Inhibidores del reflujo
ZA9707969A ZA977969B (en) 1996-09-18 1997-09-04 Reflux inhibitors.
TW086113275A TW548104B (en) 1996-09-18 1997-09-12 Pharmaceutical compositions for inhibiting transient lower esophageal sphincter relaxations
IDP973172A ID19621A (id) 1996-09-18 1997-09-12 Penghambat refluks
EEP199900095A EE03952B1 (et) 1996-09-18 1997-09-15 Tagasivoolu inhibiitorid
UA99031298A UA61081C2 (uk) 1996-09-18 1997-09-15 Активний компонент для придушення тимчасових релаксацій нижнього сфінктера, спосіб такого придушення та спосіб скринінгу сполук
RU99107969/14A RU2199316C2 (ru) 1996-09-18 1997-09-15 Вещества, подавляющие рефлюкс
HU9903825A HU224968B1 (en) 1996-09-18 1997-09-15 Use of gabab receptor agonists for production of anti reflux pharmaceutical compositions
DE69724809T DE69724809T2 (de) 1996-09-18 1997-09-15 Refluxinhibitoren
NZ334495A NZ334495A (en) 1996-09-18 1997-09-15 Use of GABA receptor agonists such as substituted amino propyl acid derivatives to inhibit transient lower esophageal sphincter relaxations
SI9730594T SI0936906T1 (en) 1996-09-18 1997-09-15 Reflux inhibitors
KR1019997002239A KR100553294B1 (ko) 1996-09-18 1997-09-15 역류 억제제
KR1020057018539A KR100568659B1 (ko) 1996-09-18 1997-09-15 역류 억제제
DK97942346T DK0936906T3 (da) 1996-09-18 1997-09-15 Refluxhæmmere
CN97199600A CN1117560C (zh) 1996-09-18 1997-09-15 反流抑制剂
IL12896197A IL128961A (en) 1996-09-18 1997-09-15 Pharmaceutical preparations containing GABAß receptor agonists and their use as reuptake inhibitors
EP03013667A EP1344524B1 (en) 1996-09-18 1997-09-15 Reflux inhibitors
NZ504244A NZ504244A (en) 1996-09-18 1997-09-15 Method for the screening of inhibitors of transient lower esophageal sphincter relaxations using a GABAb receptor
AT97942346T ATE249212T1 (de) 1996-09-18 1997-09-15 Refluxinhibitoren
CA002265615A CA2265615C (en) 1996-09-18 1997-09-15 Reflux inhibitors
US08/952,400 US6117908A (en) 1996-09-18 1997-09-15 Use of GABAB receptor agonists as reflux inhibitors
TR1999/00591T TR199900591T2 (xx) 1996-09-18 1997-09-15 Geri ak�� �nleyicileri.
PT03013667T PT1344524E (pt) 1996-09-18 1997-09-15 Inibidores de refluxo
SK305-99A SK285744B6 (sk) 1996-09-18 1997-09-15 Použitie agonistov receptora GABAB ako inhibítorov refluxu
PCT/SE1997/001555 WO1998011885A1 (en) 1996-09-18 1997-09-15 Reflux inhibitors
CZ0093099A CZ299997B6 (cs) 1996-09-18 1997-09-15 Inhibitory refluxu
AU44064/97A AU714370B2 (en) 1996-09-18 1997-09-15 Reflux inhibitors
EP97942346A EP0936906B1 (en) 1996-09-18 1997-09-15 Reflux inhibitors
BR9711400A BR9711400A (pt) 1996-09-18 1997-09-15 Uso de um agonista receptor gabab ou de um sal farmaceuticamente aceit vel ou de um isÄmero Äptico do dito agonista receptor gabab e processos para a inibi-Æo de relaxamentos do esfincter esofagiano transiente inferior e para a sele-Æo de composto que sÆo inibidores de relaxamentos de esfincter esofagiano transiente inferior
DE69736445T DE69736445T2 (de) 1996-09-18 1997-09-15 Refluxinhibitoren
ES97942346T ES2206749T3 (es) 1996-09-18 1997-09-15 Inhibidores del reflujo.
AT03013667T ATE334700T1 (de) 1996-09-18 1997-09-15 Refluxinhibitoren
ES03013667T ES2268227T3 (es) 1996-09-18 1997-09-15 Inhibidores del reflujo.
PT97942346T PT936906E (pt) 1996-09-18 1997-09-15 Inibidores do refluxo
PL97332497A PL190028B1 (pl) 1996-09-18 1997-09-15 Zastosowanie agonisty receptora GABA
DK03013667T DK1344524T3 (da) 1996-09-18 1997-09-15 Refluksinhibitorer
SI9730749T SI1344524T1 (sl) 1996-09-18 1997-09-15 Inhibitorji refluksa
JP51458198A JP4098832B2 (ja) 1996-09-18 1997-09-15 逆流抑制剤
MYPI97004296A MY122020A (en) 1996-09-18 1997-09-16 Use of gabab receptor agonists as reflux inhibitors
SA97180522A SA97180522B1 (ar) 1996-09-18 1997-10-27 مثبطات الترجيع reflux
IS5001A IS2329B (is) 1996-09-18 1999-03-15 Bakflæðishemlar
NO19991287A NO326837B1 (no) 1996-09-18 1999-03-17 Anvendelse av GABAB-reseptoragonister for inhibering av transiente relaksjoner av nedre osofagfinkter
HK00101114A HK1022100A1 (en) 1996-09-18 2000-02-24 Reflux inhibitors
US09/658,242 US6664069B1 (en) 1996-09-18 2000-09-08 Use of GABAB receptor agonists in the screening of compounds which are reflux inhibitors
HK03109347A HK1057004A1 (en) 1996-09-18 2003-12-23 Reflux inhibitors
IS8623A IS2538B (is) 1996-09-18 2007-03-19 Bakflæðishemlar

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603408A SE9603408D0 (sv) 1996-09-18 1996-09-18 Medical use

Publications (1)

Publication Number Publication Date
SE9603408D0 true SE9603408D0 (sv) 1996-09-18

Family

ID=20403936

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9603408A SE9603408D0 (sv) 1996-09-18 1996-09-18 Medical use

Country Status (35)

Country Link
US (2) US6117908A (sv)
EP (2) EP0936906B1 (sv)
JP (1) JP4098832B2 (sv)
KR (2) KR100568659B1 (sv)
CN (1) CN1117560C (sv)
AR (1) AR007747A1 (sv)
AT (2) ATE249212T1 (sv)
AU (1) AU714370B2 (sv)
BR (1) BR9711400A (sv)
CA (1) CA2265615C (sv)
CZ (1) CZ299997B6 (sv)
DE (2) DE69736445T2 (sv)
DK (2) DK1344524T3 (sv)
EE (1) EE03952B1 (sv)
ES (2) ES2268227T3 (sv)
HK (2) HK1022100A1 (sv)
HU (1) HU224968B1 (sv)
ID (1) ID19621A (sv)
IL (1) IL128961A (sv)
IS (2) IS2329B (sv)
MY (1) MY122020A (sv)
NO (1) NO326837B1 (sv)
NZ (2) NZ504244A (sv)
PL (1) PL190028B1 (sv)
PT (2) PT1344524E (sv)
RU (1) RU2199316C2 (sv)
SA (1) SA97180522B1 (sv)
SE (1) SE9603408D0 (sv)
SI (2) SI0936906T1 (sv)
SK (1) SK285744B6 (sv)
TR (1) TR199900591T2 (sv)
TW (1) TW548104B (sv)
UA (1) UA61081C2 (sv)
WO (1) WO1998011885A1 (sv)
ZA (1) ZA977969B (sv)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69722426T3 (de) 1996-07-24 2015-05-07 Warner-Lambert Company LLC (n.Ges. des Staates Delaware) Isobutylgaba und dessen derivate zur schmerzbehandlung
AU8668598A (en) 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
SE9904507D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
US7319095B2 (en) * 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
TWI256314B (en) * 2000-02-09 2006-06-11 Mitsubishi Pharma Corp Preventive-therapeutical medicament for gastroesophageal reflux disease
EP1401423A4 (en) * 2001-05-29 2006-08-16 Depomed Dev Ltd METHOD FOR THE TREATMENT OF GASTROÖSOPHAGEAL REFLUX DISEASE AND NURSING ACID BREAKDOWN
SE0102058D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts II
SE0102057D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts I
AR033779A1 (es) * 2001-06-08 2004-01-07 Astrazeneca Ab Compuestos utiles en la enfermedad de reflujo
SE0102055D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Compounds
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
SE0201940D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
SE0201939D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination
SE0201943D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New use
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
AU2003303040B2 (en) * 2002-12-13 2009-04-23 Warner-Lambert Company Llc Pregabalin derivatives for the treatment of fibromyalgia and other disorders
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
BRPI0413756A (pt) * 2003-08-20 2006-10-31 Xenoport Inc composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica
KR20060120612A (ko) * 2003-09-12 2006-11-27 얀센 파마슈티카 엔.브이. 키메라 ｇａｂａｂ 수용체
US20050220863A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
US7566738B2 (en) * 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006071186A1 (en) * 2004-12-27 2006-07-06 Astrazeneca Ab Use of gabab receptor agonists
KR20080091452A (ko) * 2005-12-23 2008-10-13 아스트라제네카 아베 위장 장애의 치료를 위한 이미다졸 유도체
KR20080090449A (ko) * 2005-12-23 2008-10-08 아스트라제네카 아베 Ｇｅｒｄ 및 ｉｂｓ의 치료를 위한 피라졸
EP1968947A1 (en) * 2005-12-23 2008-09-17 AstraZeneca AB Gaba-b receptor modulators
BRPI0620373A2 (pt) * 2005-12-23 2011-11-08 Astrazeneca Ab composto e sais farmaceuticamente e farmacologicamente aceitáveis dos mesmos, e enantiÈmeros do composto e sais dos mesmos, uso dos mesmos, opcionalmente em combinação com um agonista do receptor de gabab,e , composição farmaceutica
CA2631991A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Heterocyclic gaba-b modulators
US7585996B2 (en) * 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
NZ598728A (en) 2006-12-22 2013-09-27 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
TWI369982B (en) * 2007-01-11 2012-08-11 Xenoport Inc Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
RU2009138135A (ru) * 2007-04-18 2011-05-27 Астразенека Аб (Se) Ксантиновые соединения, обладающие положительным аллостерическим модуляторным действием в отношении gabab
WO2008157408A2 (en) * 2007-06-15 2008-12-24 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
CN101743011A (zh) * 2007-07-25 2010-06-16 阿斯利康(瑞典)有限公司 (3-氨基-2-氟丙基)次膦酸用于治疗非糜烂性反流病的用途
WO2009061934A1 (en) * 2007-11-06 2009-05-14 Xenoport, Inc. Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
TWI380812B (zh) * 2008-01-25 2013-01-01 Xenoport Inc （３ｓ）-胺甲基-５-甲基己酸前藥之晶形及使用方法
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
US20100137442A2 (en) * 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
US8993639B2 (en) * 2008-03-20 2015-03-31 Burt Shulman Compound and method for treatment of gastroesophageal reflux
US7989641B2 (en) 2008-08-07 2011-08-02 Xenoport, Inc. Methods of synthesizing N-hydroxysuccinimidyl carbonates
US8299291B2 (en) * 2008-08-07 2012-10-30 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
KR20110117216A (ko) * 2009-03-03 2011-10-26 제노포트 인코포레이티드 Ｒ-바클로펜 전구약물의 서방형 경구 투약 형태
US8344028B2 (en) * 2009-04-17 2013-01-01 Xenoport, Inc. Gamma-amino-butyric acid derivatives as GABAB receptor ligands
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
US8580850B2 (en) 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
WO2013180796A1 (en) 2012-06-01 2013-12-05 Lynn Health Science Institute, Inc. Methods for treating insomnia
TW202412754A (zh) * 2022-06-07 2024-04-01 瑞士商意梭凱普公司 應用於食道黏膜的包含逆流抑制劑的藥物傳遞系統

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0250572A1 (en) * 1986-01-03 1988-01-07 The University Of Melbourne Gastro-oesophageal reflux composition
NO882881L (no) * 1988-06-29 1990-01-02 Trond Nilsen Anordning for lengdekorrugering av metallplater.
AU5106790A (en) * 1989-02-03 1990-09-05 Cambridge Neuroscience Research, Inc. Method of screening and classifying compounds
GB9117716D0 (en) * 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
EP0713698B1 (en) * 1992-01-22 2002-04-03 Glaxo Group Limited Medical use of atypical beta-adrenoceptor agonists
GB9408064D0 (en) * 1994-04-22 1994-06-15 Merck Sharp & Dohme Nucleic acids
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions

Also Published As

Publication number Publication date
DE69724809T2 (de) 2004-07-15
HUP9903825A3 (en) 2001-06-28
EE03952B1 (et) 2003-02-17
PL332497A1 (en) 1999-09-13
CA2265615A1 (en) 1998-03-26
IL128961A (en) 2004-08-31
SI1344524T1 (sl) 2006-12-31
NO991287L (no) 1999-03-17
KR100553294B1 (ko) 2006-02-22
KR20050101237A (ko) 2005-10-20
SA97180522B1 (ar) 2006-04-04
CZ299997B6 (cs) 2009-01-14
ATE249212T1 (de) 2003-09-15
EE9900095A (et) 1999-10-15
TW548104B (en) 2003-08-21
BR9711400A (pt) 1999-08-17
AU714370B2 (en) 1999-12-23
AU4406497A (en) 1998-04-14
SK285744B6 (sk) 2007-07-06
HU224968B1 (en) 2006-04-28
CA2265615C (en) 2007-01-30
CN1117560C (zh) 2003-08-13
JP2001501604A (ja) 2001-02-06
DK1344524T3 (da) 2006-10-30
RU2199316C2 (ru) 2003-02-27
DK0936906T3 (da) 2003-11-24
HK1022100A1 (en) 2000-07-28
EP1344524B1 (en) 2006-08-02
SI0936906T1 (en) 2004-02-29
ES2268227T3 (es) 2007-03-16
UA61081C2 (uk) 2003-11-17
NZ504244A (en) 2000-09-29
ZA977969B (en) 1998-03-18
IS2538B (is) 2009-09-15
ATE334700T1 (de) 2006-08-15
MY122020A (en) 2006-03-31
PT1344524E (pt) 2006-11-30
ID19621A (id) 1998-07-23
WO1998011885A1 (en) 1998-03-26
NO991287D0 (no) 1999-03-17
IS5001A (is) 1999-03-15
CN1237105A (zh) 1999-12-01
US6117908A (en) 2000-09-12
EP1344524A1 (en) 2003-09-17
DE69724809D1 (de) 2003-10-16
IS8623A (is) 2007-03-19
EP0936906A1 (en) 1999-08-25
SK30599A3 (en) 2000-01-18
EP0936906B1 (en) 2003-09-10
HK1057004A1 (en) 2004-03-12
ES2206749T3 (es) 2004-05-16
JP4098832B2 (ja) 2008-06-11
TR199900591T2 (xx) 1999-07-21
HUP9903825A2 (hu) 2001-05-28
CZ93099A3 (cs) 1999-09-15
US6664069B1 (en) 2003-12-16
PT936906E (pt) 2003-12-31
KR100568659B1 (ko) 2006-04-07
PL190028B1 (pl) 2005-10-31
NZ334495A (en) 2000-09-29
NO326837B1 (no) 2009-02-23
AR007747A1 (es) 1999-11-10
DE69736445T2 (de) 2007-03-15
IS2329B (is) 2008-01-15
KR20000036185A (ko) 2000-06-26
IL128961A0 (en) 2000-02-17
DE69736445D1 (de) 2006-09-14

Similar Documents

Publication Publication Date Title
SE9603408D0 (sv) Medical use
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE69820632D1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
ATE204754T1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE59203983D1 (de) Endoskopische Koagulationsfasszange.
ATE232865T1 (de) 1,4-diazabicyclo(3.2.2)nonan-4-carboxylat und carboxamidderivate, ihre herstellung und therapeutische verwendung
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
BR9809185A (pt) Diidropiranos fundidos
BR9813540A (pt) Produtos de condensação de n-benzil-3-indenilacetamidas substituìdos com aldeìdos heterocìclicos para neoplasia
IS5161A (is) Tetrahýdrópýridóefnasambönd
ES2184097T3 (es) Nuevos compuestos.
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
ATE277006T1 (de) (poly)thia-alkin-verbindungen und ihre derivate, diese enthaltende zusammensetzungen und ihre anwendung
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
ATE255094T1 (de) Piperazinderivate zur behandlung der niedrigen harnwege
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
BR9708595A (pt) Utilização de derivados de 2,5- di-hidroxibenzenossulfonicos
TR199802200A2 (xx) S�lfonamid s�bstit�e edilmi� benzopiran t�revleri, �retilme y�ntemi.
DE69918541D1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
TR199701605A2 (xx) S�lfonamid-substit�e edilmi� bile�ikler
ATE204167T1 (de) Antikonvulsive derivate zur behandlung von psoriasis